Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab

Annals of Oncology

Volumn 21, Issue 7, 2010, Pages 1455-1461

  Foley, K A ^a   Wang, P F ^b   Barber, B L ^b   Long, S R ^c   Bagalman, J E ^c   Wagner, V ^b   Song, X ^c   Zhao, Z ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c Healthcare Division   (United States)

Author keywords

Cetuximab; Claims data; Colorectal cancer; Infusion reaction

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CETUXIMAB; CORTICOSTEROID; GLUCAGON; HYPERTENSIVE FACTOR;

ADULT; ALGORITHM; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOSPASM; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HEART ARREST; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; INFUSION REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY;

EID: 77954260107     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp535     Document Type: Article

References (13)

1. American Cancer Society. Making treatment decisions: monoclonal antibodies 2009; http://www.cancer.org (10 November 2009, date last accessed).
2. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601-609.
3. Schwartzberg LS, Stepanski EJ, Fortner BV et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 2008; 16: 393-398.
4. Schwartzberg LS, Stepanski EJ, Walker MS et al. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer 2009; 17: 91-98.
5. O'Neil BH, Allen R, Spigel DR et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25: 3644-3648.
6. Allen RM, Goldberg RM, Berlin J et al. Unusually high rates of hypersensitivity to cetuximab in the middle-southern United States: association with atopic phenotype. J Clin Oncol 2007; 25 (20 Suppl): 9051.
7. Cetuximab Package Insert. http://www.fda.gov/cder/foi/label/2004/1250841bl.pdf (25 February 2009, date last accessed).
8. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002; 29: 55-60.
9. Colwell HH, Mathias SD, Ngo NH et al. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. J Infus Nur 2007; 30: 153-160.
10. Kang SP, Saif MW. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer-identification, prevention, and management. J Support Oncol 2007; 5: 451-457.
11. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13: 725-732.
12. Nordstrom BL, Norman HS, Dube TJ et al. Identification of abacavir hypersensitivity reaction in health care claims data. Pharmacoepidemiol Drug Saf 2007; 16(3): 289-296.
13. Curtis JR, Martin C, Saag K et al. Confirmation of administrative claimsidentified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease modifying antirheumatic drugs. Arthritis Rheum 2007; 57(2): 343-346.2